Medicare Enrolled
Dr. Carter King, MD
Cardiovascular Disease · Dallas, TX
Practice pattern: Cardiac & Cardiac— Practice combining cardiac and cardiac services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. King from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. King? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. King
Dr. Carter King is a cardiovascular disease in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. King performed 1,726 Medicare services across 1,475 unique beneficiaries.
Between the years covered by Open Payments, Dr. King received a total of $60,449 from 51 pharmaceutical and/or device companies across 799 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. King is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ 1,726 Medicare services$ $60,449 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,726
Medicare services
Bottom 45% in TX for cardiovascular disease
1,475
Unique beneficiaries
$96
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~91 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) | 404 | $86 | $323 |
| Echocardiogram, transthoracic | 130 | $138 | $734 |
| Regadenoson injection (Lexiscan) for heart stress test | 92 | $43 | $66 |
| New patient office visit (45-59 min) | 83 | $109 | $500 |
| Hospital follow-up visit, high complexity | 83 | $94 | $342 |
| Electrocardiogram (EKG), 12-lead | 78 | $10 | $65 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 65 | $10 | $131 |
| Hospital follow-up visit, moderate complexity | 55 | $62 | $238 |
| Initial hospital admission, high complexity | 51 | $131 | $670 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 49 | $18 | $222 |
| Ultrasound of heart blood flow, valves and chambers | 47 | $39 | $241 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 47 | $170 | $781 |
| Ultrasound of both sides of head and neck blood flow | 39 | $140 | $789 |
| Office visit, established patient (20-29 min) | 39 | $56 | $218 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 37 | $46 | $298 |
| Office visit, established patient, complex (40-54 min) | 34 | $120 | $435 |
| Cardiac catheterization | 31 | $178 | $763 |
| Ultrasound of heart, follow-up | 28 | $20 | $66 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 26 | $6 | $19 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 24 | $352 | $1,249 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 24 | $50 | $268 |
| Replacement of aortic valve through the skin and femoral artery | 22 | $570 | $4,196 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 21 | $68 | $278 |
| Coronary stent placement | 19 | $395 | $1,876 |
| Heart muscle strain imaging | 19 | $29 | $103 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 18 | $10 | $48 |
| Hospital follow-up visit, low complexity | 17 | $37 | $129 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 16 | $7 | $89 |
| Ultrasound of heart with probe in esophagus, with report | 16 | $84 | $281 |
| New patient office visit, complex (60-74 min) | 16 | $156 | $622 |
| Initial hospital admission, moderate complexity | 16 | $96 | $455 |
| Ultrasound of leg arteries or artery grafts | 15 | $189 | $997 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 15 | $139 | $813 |
| 3d radiographic procedure | 14 | $7 | $25 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 13 | $19 | $82 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $10 | $88 |
| Repair of left upper heart chamber with implant with review by radiologist | 11 | $595 | $2,045 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
18.8% high complexity
21.5% medium
59.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$60,449
Total received (2018-2024)
Avg $8,636/year across 7 years
Top 10% in TX for cardiovascular disease
51
Companies
799
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$33,148 (54.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,418 (18.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,411 (13.9%)
Scientific / Research
Research funding and grants
$7,473 (12.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$13,451
2023$14,215
2022$3,837
2021$8,291
2020$1,749
2019$9,494
2018$9,412
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Medtronic, Inc.
$17,422
Abbott Laboratories
$12,208
Edwards Lifesciences Corporation
$10,199
Medtronic Vascular, Inc.
$9,957
ABIOMED
$1,648
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$1,293
Janssen Pharmaceuticals, Inc
$942
Novartis Pharmaceuticals Corporation
$772
BOSTON SCIENTIFIC CORPORATION
$561
Shockwave Medical, Inc
$530
Boston Scientific Corporation
$471
E.R. Squibb & Sons, L.L.C.
$367
AstraZeneca Pharmaceuticals LP
$360
Merck Sharp & Dohme LLC
$347
PFIZER INC.
$310
Cardiovascular Systems Inc.
$302
Actelion Pharmaceuticals US, Inc.
$284
Amgen Inc.
$270
Philips Electronics North America Corporation
$213
Amarin Pharma Inc.
$187
Boehringer Ingelheim Pharmaceuticals, Inc.
$177
Intact Vascular, Inc.
$175
HeartFlow, Inc.
$168
BIOTRONIK INC.
$157
SCPHARMACEUTICALS INC.
$105
ShockWave Medical, Inc
$103
Itamar Medical Inc
$95
Novo Nordisk Inc
$70
Bard Peripheral Vascular, Inc.
$70
Impulse Dynamics (USA) Inc.
$60
CHIESI USA, INC.
$59
Daiichi Sankyo Inc.
$55
Chiesi USA, Inc.
$51
Biosense Webster, Inc.
$40
iRhythm Technologies, Inc.
$40
Philips North America LLC
$36
Teleflex LLC
$32
Astellas Pharma US Inc
$32
Cagent Vascular INC
$31
SANOFI-AVENTIS U.S. LLC
$31
AngioDynamics, Inc.
$30
Regeneron Healthcare Solutions, Inc.
$25
Innovation Technologies Inc
$24
La Jolla Pharmaceutical Company
$21
Siemens Medical Solutions USA, Inc.
$20
MEDICOMP INC
$20
Bardy Diagnostics, Inc.
$20
Penumbra, Inc.
$20
AtriCure, Inc.
$14
Tactile Systems Technology Inc
$13
Merck Sharp & Dohme Corporation
$11
Top 3 companies account for 65.9% of total payments
Associated products mentioned in payments ›
(4067) Tack Endovascular Systems BTK · (5044) MCOT · (6536) Phoenix · (9282) Turbo Power · 3F · ACCENT · AGILIS HISPRO · ALLURE · AMPLATZER · AMPLATZER AMULET · AMPLATZER Occluders · ANGIOJET · ASSURITY · ATRICURE ATRICLIP LAA EXCLUSION · Artis Q · Auryon Laser System 100-120 Vac · BRILINTA · CAMZYOS · CARDIOMEMS · CLEVIPREX · CLEVIPREX 50MG/100ML · CLINICAL TRIAL PRODUCT · COREVALVE EVOLUT R · CardioMEMS HF System · Carnation Ambulatory Monitor · CartoSound · ClosureFast · CoreValve Evolut · Corlanor · Coronary Orbital Atherectomy System · DYNAGEN · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · EMBLEM · EMBLEM MRI S-ICD · EMBLEM SICD ELECTRODE DELIVERY SYSTEM · ENTRESTO · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · FARXIGA · FFRct · FLEXITOUCH · FORTIFY ASSURA · FUROSCIX · GALLANT · GENERAL STRUCTURAL HEART · GENERAL ANGIOGRAPHY · GENERAL ATHERECTOMY · GIAPREZA · Hancock · HawkOne · HeartMate 3 Left Ventricular Assist Device · IGT D Therapy · IN.PACT Admiral · INGEVITY · INJECTAFER · INNOVA · IRRISEPT · Impella · Indigo System · JARDIANCE · JETSTREAM · JOT DX · KENGREAL · KENGREAL 50MG/10ML L · LEQVIO · LEXISCAN · LINQ II · LUX-Dx Insertable Cardiac Monitor · LifeVest · MANTA · MERLIN@HOME · MITRACLIP · MULTAQ · Merlin Connectivity and Remote · Micra · Mitra Clip system · MitraClip System · OPTIMIZER · OPTISURE · Occluders · Orsiro Mission · Ozempic · PASCAL · PORTICO · PRADAXA · PRALUENT · Perclose ProGlide suture mediated closure system · Peripheral Orbital Atherectomy System · QT Vascular Chocolate PTA Balloon · RESOLUTE ONYX · ROTABLATOR · ROTALINK · Repatha · Resolute · Rybelsus · SAPIEN 3 Ultra RESILIA · SHOCKWAVE IVL SYSTEM WITH THE SHOCKWAVE C2 CORONARY IVL CATHETER · Serrantor · Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter · TELEPATCH CARDIAC MONITOR · THORATEC HEARTMATE 3 LVAS IMPLANT KIT · TURNPIKE · Tack Endovascular System · UPTRAVI · VERQUVO · VYNDAQEL · Vascepa · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · WOLVERINE · WatchPATONE · XARELTO · XIENCE SIERRA · XIENCE SKYPOINT · Xience Sierra Coronary Stent System · ZIO XT Patch
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (55%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for cardiovascular disease in TX.
Equivalent to $3,502 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
306
Per 100K population
11.8
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. King is a cardiac & cardiac specialist, with moderate Medicare volume, and high industry engagement (low-engagement, top 10%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. King experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. King performed 404 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. King receive payments from pharmaceutical companies?
Yes. Dr. King received a total of $60,449 from 51 companies across 799 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. King's costs compare to other cardiovascular diseases in Dallas?
Dr. King's average Medicare payment per service is $96. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. King) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Dallas
Browse cardiovascular diseases in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc..
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
Edwards Lifesciences Corporation Payments to Doctors
See all physicians who received payments from Edwards Lifesciences Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology